Why SMART About Second-Line Treatment When First-Line Treatment Is Being Ignored?
To the Editor:
In a recent issue of CHEST (January 2006), 1 the Salmeterol Multicenter Asthma Research Trial (or SMART) demonstrated that the regular use of a twice-daily regimen of salmeterol in asthmatic patients was associated with an unnerving increase in respiratory-related and asthma-related deaths, combined asthmarelated deaths, or life-threatening experiences. However, surely one of the other most concerning observations was the fact that at study entry only 47% individuals in both the active treatment and placebo groups were receiving regular therapy with inhaled corticosteroids. Thus, Ͼ 26,000 subjects with asthma of approximately 16 years duration with a mean peak expiratory flow of 84% predicted were randomized to receive either a placebo inhaler or a long-acting ␤ 2 -agonist over a 28-week period without therapy with inhaled corticosteroids.
Since guidelines 2,3 advocate the early use of inhaled corticosteroids in the treatment of asthma, it is therefore incredulous to consider that the investigators felt it reasonable to enroll a majority of individuals who were being inappropriately managed in the community. Perhaps rigorous advertising campaigns are required to emphasize that therapy with inhaled corticosteroids is a long-established, effective, safe, and inexpensive treatment for the management of asthma. And perhaps clinicians and the pharmaceutical industry require reminding too. To the Editor:
We thank Dr. Currie for his comments regarding the Salmeterol Multicenter Asthma Research Trial (SMART). It is impor-tant to note that SMART was conducted in the United States and was designed in collaboration with the US Food and Drug Administration to be a real-world, observational study evaluating the addition of salmeterol or placebo to usual pharmacotherapy for asthma.
The protocol required a physician diagnosis of asthma and current use of a prescription asthma medication. In addition, investigators were provided with current prescribing information for salmeterol and were asked to use their clinical judgment in determining which patients were appropriate for study inclusion. Therefore, patients could have been receiving inhaled corticosteroid (ICS) therapy to which either salmeterol or placebo would have been added. In addition, SMART was initiated in 1996, which was prior to the 1997 revision of the National Institutes of Health asthma guidelines. 1 Furthermore, the reported use of ICSs at baseline in SMART (47%) was much higher than the average ICS use (10 to 20%) as reported by a large national survey in 1998. 2 In summary, although SMART was not designed to specifically evaluate the addition of salmeterol or placebo to current ICS therapy, we agree with Dr. Currie's overall conclusions and current guideline recommendations that the most effective therapy for persistent asthma is ICSs; with the addition of a longacting ␤ 2 -agonist, as necessary, for treatment in patients with moderate and severe persistent asthma. 3 
